An Early Phase 1 interventional study of Regional Anesthesia and Hydromorphone Patient Controlled Analgelsic in Substance Use Disorder (SUD), sponsored by Medical College of Wisconsin. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Medical College of Wisconsin · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.
Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 1,233rd largest by planned enrollment of the 1,447 interventional ones that give a count, is one of 81 that started in 2025, is one of 131 in phase 1, reaches primary completion later than 177 of the 312 other live ones, and was the 1,405th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–120
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–65 · Healthy volunteers
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,589 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 172 · Phase 2 242 · Phase 3 79 · Phase 4 67
First in 1990; this study’s year is marked. 81 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 104 across the 1,447 interventional studies, 234 across the 137 observational. Of the 1,175 that completed or were terminated, 376 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 1,589 have an industry lead sponsor. The 10 most frequent:
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 123 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 58 (76%) have results posted.
Medical College of Wisconsin has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
100 of the studies in Substance-Related Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07566273Cornell UniversityMicropractices for Unhoused LGBTQ Youth | 2026-11 |
| NCT05897164Evidence-Based Practice Institute, Seattle, WAMobile Technology to Reduce Teen Substance Misuse | 2026-11-30 |
| NCT04317482University of ArkansasThe Human Stress Response in a Simulated ED Setting | 2026-12 |
| NCT05713695University of Massachusetts, WorcesterSupporting Treatment Access and Recovery Through Linkage and Support | 2026-12 |
| NCT03539575Yale UniversityCB1R in Synthetic Psychoactive Cannabinoids | 2026-12 |
Add all 100 to your calendar (.ics) → With an account.
Among the 1,589 studies in Substance-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy of three different modalities of post-operative pain control in parturient with opioid use disorders. The investigators aim to determine whether the different approach utilized show better outcomes with pain management and if there are any association with reduction of symptoms of anxiety, depression, and overall well-being.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.
Drug: Regional Anesthesia
A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.
Procedure: Epidural local anesthetic infusion
A subset of participants (n=15) will be divided into three different arms: A.) Postoperative Epidural infusion for 24-36hrs B.) Hydromorphone Patient Controlled Analgesia (PCA) with Preservative free Morphine via epidural for 36hrs C.) Transverse abdominal Plane(TAP) Block with long acting Exparel.
Drug: Hydromorphone Patient Controlled Analgelsic
Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.
This group will be administered epidural PCA as a modality for pain control post cesarian section
Epidural group will receive pain control via a local anesthetic intermediate bolus infusion
Number of participants with Change in pain assessment scores from baseline post surgery
Number of participants with significant change in pain assessment scores and any association with reduction of symptoms of anxiety, depression, and overall well-being.
Time frame: immediately after the study intervention and up to post op day 2
Plan to share: Yes — De-identified patient data, statistical analysis and conclusions.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.
Of 30 non-industry phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's planned 35 months is close to that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical College of Wisconsin →